A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status.

被引：4
|
作者：
Khosravan, Reza
Huang, Xin
Wiltshire, Robin
Lechuga, Mariajose
Motzer, Robert John
机构：
[1] Pfizer Oncol, La Jolla, CA USA
[2] Pfizer Ltd, Surrey, England
[3] Pfizer Italia Srl, Milan, Italy
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 05期
关键词：
D O I：
10.1200/jco.2012.30.5_suppl.363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
363
引用
收藏
页数：1
相关论文
共 33 条
  • [31] Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048)
    Valero, V.
    Bosserman, L. D.
    Yardley, D. A.
    Roche, H. H.
    Thomas, E.
    Vahdat, L. T.
    Mukhopadhyay, P.
    Opatt, D. M.
    Peck, R. A.
    Sparano, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB AND SUNITINIB IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED/METASTATIC INTERMEDIATE- OR POOR (I/P)-RISK RENAL CELL CARCINOMA (1L ARCC) BASED ON 5-YEAR MINIMUM FOLLOW-UP DATA FROM CHECKMATE 214
    Qendri, V
    May, J. R.
    Ejzykowicz, F.
    Kurt, M.
    Cakar, E.
    Klijn, S.
    VALUE IN HEALTH, 2022, 25 (01) : S24 - S24
  • [33] Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)
    Escudier, B.
    Motzer, R. J.
    Dyer, M.
    May, J. R.
    Ejzykowicz, F.
    Kurt, M.
    Lee, C-W.
    Wang, P.
    Testa, E.
    Sharpe, D. J.
    George, S.
    Tannir, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1212 - S1212
1234